DAIC

MAY 6, 2024

We are committed to protecting the future commercial value of our innovative PH-HFpEF treatment,” said Chris Giordano , President & Chief Executive Officer of Tenax Therapeutics. Getty Images milla1cf Mon, 05/06/2024 - 10:48 May 6, 2024 — Tenax Therapeutics, Inc. ,

Preserved Ejection Fraction 105

Preserved Ejection Fraction Heart Failure Pulmonary Hypertension 105

Circulation

NOVEMBER 11, 2024

Introduction:Inflammation is a key driver in the development of pulmonary arterial hypertension (PAH). Recent studies have indicated that modulating the intestinal microbiome may be an innovative approach to mitigate systemic inflammation in PAH. The pulmonary vasculature was evaluated histologically. of which are fungi.

Pulmonary 40

Pulmonary Hypertension Innovation Exercise 40

DAIC

JUNE 27, 2024

Anumana has received FDA Breakthrough Device Designation for four of its algorithms: low ejection fraction, pulmonary hypertension , cardiac amyloidosis, and hyperkalemia. Its ECG-AI platform won the 2024 MedTech Breakthrough Award for “Best New Technology Solution- Cardiology.”

Technology 105

Technology Heart Rhythm Innovation Heart Failure 105

Cardiometabolic Health Congress

JULY 17, 2024

February 2024 FDA Approvals: Innovations in Cardiovascular Interventions XACT Carotid Stent System (Approved: 02/07/2024) This approval expands the indications to be used during a Transcarotid Artery Revascularization (TCAR) procedure to prevent future strokes.

Tricuspid 59

Tricuspid Open-Heart Surgery Kidney Disease Pediatrics 59

Dr. S. Venkatesan MD

APRIL 18, 2024

This is to create a small regulatory orifice in the IAS ( A complicated term for a small ASD ) to decompress the LA and reduce pulmonary congestive symptoms. May be, it will come soon in the innovative lanes of cardiology. Antonio F Corno, et al JTVS 200 3 Remote controlled pulmonary artery banding JAMA Cardiol.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Pulmonary Congenital Heart Disease VSD 40

DAIC

JUNE 24, 2024

Food and Drug Administration ( FDA ) of the company's Cordella Pulmonary Artery (PA) Sensor System for the treatment of New York Heart Failure (NYHA) class III heart failure patients. milla1cf Mon, 06/24/2024 - 20:21 June 24, 2024 — Endotronix, Inc. ,

Heart Failure 109

Heart Failure Reimbursement Heart Transplant Pulmonary 109